基于血红蛋白的氧载体(hbc -201)和递增剂量的重组因子VIIa (rFVIIa)作为一种新的院前复苏液体在猪严重不受控制的出血模型中。

Artificial cells, blood substitutes, and immobilization biotechnology Pub Date : 2011-04-01 Epub Date: 2010-07-20 DOI:10.3109/10731199.2010.501755

Anke Scultetus, Francoise Arnaud, Lewis Kaplan, Aryeh Shander, Nora Philbin, Jennifer Rice, Richard McCarron, Daniel Freilich

{"title":"基于血红蛋白的氧载体(hbc -201)和递增剂量的重组因子VIIa (rFVIIa)作为一种新的院前复苏液体在猪严重不受控制的出血模型中。","authors":"Anke Scultetus, Francoise Arnaud, Lewis Kaplan, Aryeh Shander, Nora Philbin, Jennifer Rice, Richard McCarron, Daniel Freilich","doi":"10.3109/10731199.2010.501755","DOIUrl":null,"url":null,"abstract":"Exsanguinating hemorrhage and unavailability of blood are major problems in pre-hospital trauma care. We investigated if combining rFVIIa with HBOC-201 reduces blood loss and improves physiologic parameters compared to HBOC alone. Swine underwent liver injury and were resuscitated with HBOC-201 alone or HBOC+90, 180 or 360 μg/kg rFVIIa before hospital arrival at 240 min; animals survived to 72 hours. Blood loss was reduced; MAP, CI, transcutaneous oxygen saturation, and 72-hour survival improved in the 90 and 180 μg/kg rFVIIa groups. Lactate was cleared faster in the HBOC+rFVIIa 90 μg/kg group. Verification in a large, well-powered study is indicated.","PeriodicalId":8413,"journal":{"name":"Artificial cells, blood substitutes, and immobilization biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10731199.2010.501755","citationCount":"4","resultStr":"{\"title\":\"Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage.\",\"authors\":\"Anke Scultetus, Francoise Arnaud, Lewis Kaplan, Aryeh Shander, Nora Philbin, Jennifer Rice, Richard McCarron, Daniel Freilich\",\"doi\":\"10.3109/10731199.2010.501755\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Exsanguinating hemorrhage and unavailability of blood are major problems in pre-hospital trauma care. We investigated if combining rFVIIa with HBOC-201 reduces blood loss and improves physiologic parameters compared to HBOC alone. Swine underwent liver injury and were resuscitated with HBOC-201 alone or HBOC+90, 180 or 360 μg/kg rFVIIa before hospital arrival at 240 min; animals survived to 72 hours. Blood loss was reduced; MAP, CI, transcutaneous oxygen saturation, and 72-hour survival improved in the 90 and 180 μg/kg rFVIIa groups. Lactate was cleared faster in the HBOC+rFVIIa 90 μg/kg group. Verification in a large, well-powered study is indicated.\",\"PeriodicalId\":8413,\"journal\":{\"name\":\"Artificial cells, blood substitutes, and immobilization biotechnology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3109/10731199.2010.501755\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Artificial cells, blood substitutes, and immobilization biotechnology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/10731199.2010.501755\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2010/7/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial cells, blood substitutes, and immobilization biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/10731199.2010.501755","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2010/7/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

摘要

放血出血和血液缺乏是院前创伤护理的主要问题。我们研究了与单独使用HBOC相比，rFVIIa联合HBOC-201是否能减少失血量并改善生理参数。猪肝损伤，在到达医院240 min前分别用HBOC-201或HBOC+90、180或360 μg/kg rFVIIa进行复苏;动物存活了72小时。出血量减少;90和180 μg/kg rFVIIa组MAP、CI、经皮血氧饱和度和72小时生存率均有改善。90 μg/kg HBOC+rFVIIa组乳酸清除较快。在一个大型的，有力的研究中进行验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage.

Exsanguinating hemorrhage and unavailability of blood are major problems in pre-hospital trauma care. We investigated if combining rFVIIa with HBOC-201 reduces blood loss and improves physiologic parameters compared to HBOC alone. Swine underwent liver injury and were resuscitated with HBOC-201 alone or HBOC+90, 180 or 360 μg/kg rFVIIa before hospital arrival at 240 min; animals survived to 72 hours. Blood loss was reduced; MAP, CI, transcutaneous oxygen saturation, and 72-hour survival improved in the 90 and 180 μg/kg rFVIIa groups. Lactate was cleared faster in the HBOC+rFVIIa 90 μg/kg group. Verification in a large, well-powered study is indicated.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Artificial cells, blood substitutes, and immobilization biotechnology 工程技术-材料科学：生物材料

自引率

0.00%

发文量

审稿时长

6-12 weeks